Miami, Florida | June 18, 2026
Longeveron Inc. announced that an additional clinical data analysis from its Phase 2a CLEAR MIND trial evaluating laromestrocel (Lomecel-B™) for mild Alzheimer’s disease has been accepted for poster presentation at the 2026 Alzheimer’s Association International Conference (AAIC), scheduled for July 12–15, 2026, in London, United Kingdom. The presentation will showcase new analyses designed to further evaluate the therapeutic potential of the company’s investigational allogeneic mesenchymal stem cell (MSC) therapy in patients with early-stage Alzheimer’s disease. Acceptance at one of the world’s leading scientific meetings focused on dementia research highlights continued interest in laromestrocel’s clinical development and its potential role in addressing one of the most significant unmet needs in neurodegenerative medicine. The additional findings build upon previously reported Phase 2a clinical results that supported continued advancement of the therapy into future clinical development.
Phase 2a CLEAR MIND Trial Strengthens Clinical Evidence
The CLEAR MIND Phase 2a clinical trial evaluated the safety and therapeutic potential of laromestrocel in patients with mild Alzheimer’s disease, generating encouraging findings that were previously published in the peer-reviewed journal Nature Medicine in March 2025. According to the company, the upcoming AAIC presentation will provide additional analyses of the existing clinical dataset, offering further insight into treatment response and reinforcing evidence supporting continued development of the investigational therapy. Although the newly accepted poster focuses on expanded analysis rather than new patient enrollment, it represents another important milestone in validating the scientific findings generated during the Phase 2a program. The company believes these analyses may help strengthen the clinical foundation for future studies evaluating cell-based regenerative medicine as a potential therapeutic approach for patients experiencing early cognitive decline associated with Alzheimer’s disease.
Laromestrocel Targets Multiple Mechanisms in Neurodegenerative Disease
Laromestrocel (Lomecel-B™) is an investigational allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors. Unlike therapies targeting a single disease pathway, laromestrocel is designed to exert multiple biological mechanisms of action, including anti-inflammatory activity, tissue repair, vascular support, regenerative effects, and immune modulation. These broad biological properties have positioned the therapy as a potential candidate for treating several diseases associated with aging and tissue degeneration. In recognition of its clinical potential in Alzheimer’s disease, the U.S. Food and Drug Administration (FDA) has previously granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation, supporting accelerated development for this serious neurological condition. These regulatory designations reflect the continuing need for innovative treatment options capable of slowing disease progression or improving patient outcomes in Alzheimer’s disease.
Regenerative Medicine Pipeline Continues to Expand
Advertisement
Beyond Alzheimer’s disease, Longeveron is advancing a diversified regenerative medicine pipeline targeting multiple rare pediatric and chronic aging-related disorders. The company’s lead investigational product is currently under development for Hypoplastic Left Heart Syndrome (HLHS), Pediatric Dilated Cardiomyopathy (DCM), Aging-related Frailty, and Alzheimer’s disease. Collectively, these programs have received five FDA regulatory designations, including Orphan Drug, Rare Pediatric Disease, Fast Track, and RMAT status, highlighting the significant unmet medical needs addressed by the company’s research. Presentation of the additional Phase 2a Alzheimer’s disease analysis at AAIC 2026 represents another important step in expanding the clinical evidence supporting laromestrocel while reinforcing the growing role of regenerative stem cell therapies in the development of next-generation treatments for neurodegenerative diseases and other serious medical conditions.
Source: Longeveron, press release
